Wiggans Thomas G
Former Director at ANNX; CEO & Chairman of the Board at Dermira, Inc.; Director at ONYX PHARMACEUTICALS INC, and 2 more
- Sold, on record
- $8.3M
- Dollars the filings state
- Form 4 sales
- 34
- Latest Dec 13, 2017
- Form 144 notices
- 3
- Proposed sales
- Companies
- 5
- Filed as an executive or holder
Companies
- ANNXAnnexon, Inc.Former Director
- Dermira, Inc.CEO & Chairman of the Board
- ONYX PHARMACEUTICALS INCDirector
- Somaxon Pharmaceuticals, Inc.Director
- CONNETICS CORPChief Executive Officer
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- Dermira, Inc.199,000 shares
- Somaxon Pharmaceuticals, Inc.30,163 shares
- ONYX PHARMACEUTICALS INC27,200 shares
- CONNETICS CORP8,000 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale Dermira, Inc.Plan not statedAug 1, 2017 2017
Sold 500 shares at $27.58 ($14k)
Wiggans Thomas G, CEO & Chairman of the Board
Sold 6.1% of holdings ($226k position)7,690 shares left0.1x usual sizeFiling
- 2 Form 4 sale Dermira, Inc.UnusualSep 18, 2017 +48 days
Sold 9,500 shares at $27.51 ($261k)
Wiggans Thomas G, CEO & Chairman of the Board
Sold 41.4% of holdings ($631k position)13,427 shares left1.1x usual sizeFiling
- 3 Form 4 sale Dermira, Inc.UnusualOct 10, 2017 +22 days
Sold 5,000 shares at $27.52 ($138k)
Wiggans Thomas G, CEO & Chairman of the Board
Sold 27.1% of holdings ($507k position)13,427 shares left0.6x usual sizeFiling
- 4 Form 4 sale Dermira, Inc.UnusualNov 2, 2017 +23 days
Sold 5,000 shares at $27.52 ($138k)
Wiggans Thomas G, CEO & Chairman of the Board
Sold 27.1% of holdings ($507k position)13,427 shares left0.6x usual sizeFiling
- 5 Form 4 sale Dermira, Inc.UnusualDec 13, 2017 +41 days
Sold 5,000 shares at $27.51 ($138k)
Wiggans Thomas G, CEO & Chairman of the Board
Sold 26.8% of holdings ($513k position)13,662 shares left0.6x usual sizeFiling
- 6 Form 144 notice ANNXNoticeJul 14, 2026 +3135 days
Filed to sell 1,000 shares ($6k)
Wiggans Thomas G, Former Director
No 10b5-1 planFirst sale on recordFiling
- 7 Form 144 notice ANNXNoticeJul 15, 2026 +1 day
Filed to sell 2,000 shares ($13k)
Wiggans Thomas G, Former Director
No 10b5-1 planFirst sale on recordFiling
- 8 Form 144 notice ANNXNoticeAug 13, 2026 +29 days
Filed to sell 2,000 shares ($11k)
Wiggans Thomas G, Former Director
No 10b5-1 planFirst sale on recordFiling
Every transaction
Loading transactions…
Sales and notices (37)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | Aug 13, 2026 | ANNX | Former Director | Form 144 notice | 2,000 | $11k | Notice | SEC | |
| Jul 15, 2026 | Jul 15, 2026 | ANNX | Former Director | Form 144 notice | 2,000 | $13k | Notice | SEC | |
| Jul 14, 2026 | Jul 14, 2026 | ANNX | Former Director | Form 144 notice | 1,000 | $6k | Notice | SEC | |
| Dec 13, 2017 | Dec 15, 2017 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 5,000 | $138k | 26.8% | Unusual | SEC |
| Nov 2, 2017 | Nov 3, 2017 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 5,000 | $138k | 27.1% | Unusual | SEC |
| Oct 10, 2017 | Oct 11, 2017 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 5,000 | $138k | 27.1% | Unusual | SEC |
| Sep 18, 2017 | Sep 19, 2017 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 9,500 | $261k | 41.4% | Unusual | SEC |
| Aug 1, 2017 | Aug 2, 2017 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 500 | $14k | 6.1% | Plan not stated | SEC |
| Jul 3, 2017 | Jul 5, 2017 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 5,000 | $145k | 39.4% | Unusual | SEC |
| Jun 2, 2017 | Jun 5, 2017 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 5,000 | $138k | 39.4% | Unusual | SEC |
| May 1, 2017 | May 3, 2017 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 8,000 | $269k | 55.3% | Unusual | SEC |
| Apr 3, 2017 | Apr 4, 2017 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 8,000 | $268k | 55.3% | Unusual | SEC |
| Mar 3, 2017 | Mar 7, 2017 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 4,000 | $150k | 38.2% | Unusual | SEC |
| Mar 1, 2017 | Mar 2, 2017 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 11,000 | $369k | 63.0% | Unusual | SEC |
| Feb 1, 2017 | Feb 3, 2017 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 5,000 | $147k | 43.6% | Unusual | SEC |
| Jan 4, 2017 | Jan 5, 2017 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 8,000 | $248k | 55.3% | Unusual | SEC |
| Dec 1, 2016 | Dec 2, 2016 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 11,000 | $339k | 7.6% | Plan not stated | SEC |
| Nov 1, 2016 | Nov 2, 2016 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 11,000 | $343k | 7.0% | Plan not stated | SEC |
| Oct 3, 2016 | Oct 4, 2016 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 11,000 | $381k | 6.6% | Plan not stated | SEC |
| Sep 1, 2016 | Sep 2, 2016 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 11,000 | $348k | 6.2% | Plan not stated | SEC |
| Aug 1, 2016 | Aug 3, 2016 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 11,000 | $365k | 5.7% | Plan not stated | SEC |
| Jul 5, 2016 | Jul 6, 2016 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 11,000 | $326k | 5.4% | Plan not stated | SEC |
| Jun 1, 2016 | Jun 3, 2016 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 11,000 | $347k | 5.1% | Plan not stated | SEC |
| May 2, 2016 | May 3, 2016 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 9,000 | $226k | 4.0% | Plan not stated | SEC |
| Apr 1, 2016 | Apr 5, 2016 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 7,000 | $145k | 3.0% | Plan not stated | SEC |
| Mar 1, 2016 | Mar 2, 2016 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 7,000 | $158k | 2.9% | Plan not stated | SEC |
| Feb 1, 2016 | Feb 3, 2016 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 9,000 | $245k | 3.6% | Plan not stated | SEC |
| Jan 4, 2016 | Jan 6, 2016 | Dermira, Inc. | CEO & Chairman of the Board | Form 4 sale | 11,000 | $365k | 4.3% | Plan not stated | SEC |
| May 6, 2013 | May 8, 2013 | ONYX PHARMACEUTICALS INC | Director | Form 4 sale | 4,500 | $410k | 33.4% | Unusual | SEC |
| Apr 5, 2013 | Apr 9, 2013 | ONYX PHARMACEUTICALS INC | Director | Form 4 sale | 3,700 | $318k | 29.2% | Unusual | SEC |
| Mar 8, 2013 | Mar 11, 2013 | ONYX PHARMACEUTICALS INC | Director | Form 4 sale | 2,000 | $170k | 19.9% | Plan not stated | SEC |
| Mar 5, 2013 | Mar 5, 2013 | ONYX PHARMACEUTICALS INC | Director | Form 4 sale | 2,500 | $193k | 23.7% | Plan not stated | SEC |
| Feb 5, 2013 | Feb 6, 2013 | ONYX PHARMACEUTICALS INC | Director | Form 4 sale | 2,500 | $193k | 23.7% | Plan not stated | SEC |
| Aug 16, 2012 | Aug 17, 2012 | ONYX PHARMACEUTICALS INC | Director | Form 4 sale | 12,000 | $824k | 59.8% | Unusual | SEC |
| Dec 1, 2010 | Dec 3, 2010 | Somaxon Pharmaceuticals, Inc. | Director | Form 4 sale | 30,163 | $81k | 53.2% | Unusual | SEC |
| Mar 1, 2006 | Mar 3, 2006 | CONNETICS CORP | Chief Executive Officer | Form 4 sale | 4,000 | $64k | 1.5% | Plan not stated | SEC |
| Jan 13, 2006 | Jan 17, 2006 | CONNETICS CORP | Chief Executive Officer | Form 4 sale | 4,000 | $58k | 3.2% | Plan not stated | SEC |